乳糜泻患者的骨折风险评估:一项基于登记数据的队列研究
研究基于Manitoba BMD登记数据,纳入693例乳糜泻患者,评估乳糜泻是否独立于FRAX评分影响主要骨质疏松性骨折(MOF)风险。结果显示,未将继发性骨质疏松或骨密度(BMD)纳入FRAX计算时,乳糜泻与骨折风险升高相关(校正HR 1.43,95%CI 1.11-1.86);将继发性骨质疏松或BMD纳入FRAX后,乳糜泻不再为显著危险因素(P>0.1)。将乳糜泻作为继发性骨质疏松危险因素或纳入BMD后,FRAX可准确预测骨折风险。
要点
- 未将继发性骨质疏松或BMD纳入FRAX时,乳糜泻患者骨折风险升高(校正HR 1.43,95%CI 1.11-1.86)。
- 将继发性骨质疏松或BMD纳入FRAX计算后,乳糜泻不再为显著骨折危险因素(P>0.1)。
- 乳糜泻患者中FRAX评分每增加1个标准差,MOF风险升高(校正HR 1.66至1.80),与一般人群相似(交互作用P>0.2)。
核心结论
- 乳糜泻与主要骨质疏松性骨折风险升高相关。
- 当将乳糜泻视为继发性骨质疏松危险因素或将BMD纳入FRAX评估时,FRAX能准确预测骨折风险。
研究设计与样本
- 基于Manitoba BMD登记数据的队列研究,纳入693例乳糜泻患者,通过链接基于人群的医疗数据库识别10年内新发MOF诊断。
- 使用加拿大FRAX工具计算每例个体的10年MOF概率,并与一般人群队列比较。
主要发现
- 未将继发性骨质疏松或BMD纳入FRAX计算时,乳糜泻与骨折风险升高相关(校正HR 1.43,95%CI 1.11-1.86)。
- 将继发性骨质疏松或BMD纳入FRAX计算后,乳糜泻不再为显著骨折危险因素(P>0.1)。
- 乳糜泻患者中,FRAX评分(无论是否包含继发性骨质疏松或BMD)每增加1个标准差,MOF风险升高(校正HR 1.66至1.80),与一般人群相似(交互作用P>0.2)。
- 将乳糜泻作为继发性骨质疏松或纳入BMD后,FRAX计算的10年MOF概率(分别为10.1%和8.6%)与观察到的10年累积MOF概率(10.8%,95%CI 7.8-13.9%)接近。
关键数值与推荐
- 未将继发性骨质疏松或BMD纳入FRAX时,乳糜泻患者骨折校正HR 1.43(95%CI 1.11-1.86)。
- 将继发性骨质疏松或BMD纳入FRAX后,乳糜泻不再显著(P>0.1)。
- 乳糜泻患者FRAX评分每增加1个标准差,MOF校正HR 1.66至1.80,与一般人群交互作用P>0.2。
- FRAX预测10年MOF概率:含继发性骨质疏松为10.1%,含BMD为8.6%,观察值为10.8%(95%CI 7.8-13.9%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Celiac disease is associated with an increased fracture risk but is not a direct input to the FRAX® calculation. When celiac disease is considered as a secondary osteoporosis risk factor or BMD is included in the FRAX assessment, FRAX accurately predicts fracture risk. INTRODUCTION: The fracture risk assessment tool (FRAX®) uses clinical factors and bone mineral density (BMD) measurement to predict 10-year major osteoporotic (MOF) fracture probability. The study aim was to determine whether celiac disease affects MOF risk independent of FRAX score. METHODS: The Manitoba BMD Registry includes clinical data, BMD measurements, 10-year probability of MOF calculated for each individual using the Canadian FRAX tool and diagnosed celiac disease. Using linkage to population-based healthcare databases, we identified incident MOF diagnoses over the next 10 years for celiac disease and general population cohorts. RESULTS: Celiac disease (N = 693) was associated with increased fracture risk adjusted for FRAX score computed without secondary osteoporosis or BMD (adjusted hazard ratio [HR] 1.43, 95% confidence interval [CI] 1.11-1.86). Celiac disease was no longer a significant risk factor for fracture when secondary osteoporosis or BMD were included in the FRAX calculation (p > 0.1). In subjects with celiac disease, each SD increase in FRAX score (calculated with and without secondary osteoporosis or BMD) was associated with higher risk of incident MOF (adjusted HR 1.66 to 1.80), similar to the general population (p-interaction > 0.2). Including celiac disease as secondary osteoporosis or including BMD in FRAX 10-year MOF probability calculations (10.1% and 8.6% respectively) approximated the observed cumulative 10-year MOF probability (10.8%, 95% CI 7.8-13.9%). CONCLUSIONS: Celiac disease is associated with an increased risk of major osteoporotic fractures. When celiac disease is considered as a secondary osteoporosis risk factor or BMD is included in FRAX assessment, FRAX accurately predicts fracture risk.
引用
- Duerksen DR, Lix LM, Johansson H, et al. Fracture risk assessment in celiac disease: a registry-based cohort study. Osteoporos Int. 2020. PMID: 32748311. doi:10.1007/s00198-020-05579-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。